10 results
To investigate the effects of galantamine on cognitive impairment and visual hallucinations in Parkinson`s disease, both therapeutic (direct effect) and preventive (protection against an acute increase of dopaminergic medication used by the patient…
To replicate and extend the findings of the recent methylphenidate study in which methylphenidate was found to enhance episodic memory performance; To explore whether this effect of methylphenidate is primarily mediated by its dopaminergic action.
This is a medical-scientific research study. The purpose of the study is to investigate the effect of multiple doses of the study compound BIA 28-6156 on the pharmacokinetics of the drugs levodopa-carbidopa (Group 1) and levodopa-benserazide (Group…
The aim of this study is to improve our understanding of the mechanisms underlying altered social performance monitoring from a pharmacological perspective by directly comparing the effects of dopamine and oxytocin on individual and social…
Firstly, comparison of DTI outcome variables between the auditory nerve of a deaf ear with that of a normal ear. Secondly, in patients who receive a CI, DTI measures will be compared to measures derived from electrically evoked compound action…
to assess whether a single-dose of levodopa improves cognitive symptoms and balances goal-directed and habitual behavior.
The study consists of two phases. In the first phase, we aim to investigate whether the dopamine receptor D4 (DRD4) genotype confers differential susceptibility to the effects of early life stress on empathy and prosocial behavior more generally in…
The proposed Study J2G-MC-JZJC (hereafter referred to as JZJC) will evaluate selpercatinib in comparison to platinum-based (carboplatin or cisplatin) and pemetrexed therapy with or without pembrolizumab in patients with locally advanced or…
To investigate whether early treatment with levodopa has a delayed beneficial effect on PD symptoms and functional health, and improves the ability to (maintain) work, reduces the use of (informal) care, caregiver burden, and costs. Additionally,…
To compare EFS of participants in the primary analysis population with Stage II-IIIA RET fusion-positive NSCLC treated with selpercatinib versus placebo.